Company intelligence / Profile preview

Obsidian Software

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~120
Development stage: Other

Overview

OBX-115 demonstrated a 50% objective response rate and 33% complete response rate in heavily pre-treated metastatic melanoma patients; ongoing Phase 1/2 trials show promising early efficacy and safety results, supporting the IL2-sparing and persistent anti-tumor activity of the therapy[4][9].

Therapeutic areas: OncologyRare Diseases
Modalities: Cell therapyTumor-infiltrating lymphocyte (TIL) therapyGene therapy
Industry: Biotech

Partnerships

Bristol Myers SquibbVertex PharmaceuticalsResilience[4][9]

Beyond the preview

Go deeper on Obsidian Software.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Obsidian Software.

Explore the full profile